Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 16, 2026, 12:22 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 601–624 of 830 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Safety and Pharmacokinetics in Healthy Volunteer Subjects Clear all
Completed No phase listed Observational Accepts healthy volunteers

Extension Study to Further Evaluate the Safety, Pharmacodynamics and Pharmacokinetics of Ozanimod and Active Metabolites

NCT03665610
View directory record Official record
Conditions
Healthy Volunteers
Interventions
ozanimod
Drug
Lead sponsor
Celgene
Industry
Eligibility
18 Years to 55 Years
Enrollment
212 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2019
U.S. locations
2
States / cities
Austin, Texas • San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Feb 6, 2019 · Synced Oct 16, 2026, 12:22 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Study of TAVO103A in Healthy Volunteers

NCT05313152
View directory record Official record
Conditions
Healthy Subjects
Interventions
TAVO103A, Placebo
Drug · Other
Lead sponsor
Tavotek Biotherapeutics
Industry
Eligibility
18 Years to 65 Years
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2023
U.S. locations
1
States / cities
Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Dec 12, 2023 · Synced Oct 16, 2026, 12:22 AM EDT
Terminated Phase 1 Interventional Accepts healthy volunteers

A Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of AZD6615 in Healthy Subjects

NCT04055168
View directory record Official record
Conditions
Dyslipidemia
Interventions
AZD6615, Placebo
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
20 Years to 60 Years
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2020
U.S. locations
2
States / cities
Glendale, California • Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Dec 14, 2020 · Synced Oct 16, 2026, 12:22 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Placebo-Controlled Single Dose Study to Evaluate Safety and Pharmacokinetics of GMI-1359 in Healthy Volunteers

NCT02931214
View directory record Official record
Conditions
Healthy
Interventions
GMI-1359, Placebo
Drug
Lead sponsor
GlycoMimetics Incorporated
Industry
Eligibility
19 Years to 60 Years
Enrollment
58 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2018
U.S. locations
1
States / cities
Lincoln, Nebraska
Source: ClinicalTrials.gov public record
Updated Mar 4, 2019 · Synced Oct 16, 2026, 12:22 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study of the Safety, Pharmacokinetics, and Pharmacodynamics of CNTO 3649 in Healthy Adults and Patients With Type 2 Diabetes Mellitus

NCT00882726
View directory record Official record
Conditions
Diabetes Mellitus, Type 2
Interventions
CNTO 3649 IV (Healthy participants), CNTO 3649 SC (Healthy participants), CNTO 3649 SC (Diabetic patients), Placebo
Drug
Lead sponsor
Centocor, Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
133 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2010
U.S. locations
3
States / cities
Miramar, Florida • San Antonio, Texas • Tacoma, Washington
Source: ClinicalTrials.gov public record
Updated Dec 16, 2013 · Synced Oct 16, 2026, 12:22 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

First-In-Human Study Of Single And Multiple Ascending Doses Of PF-06751979

NCT02509117
View directory record Official record
Conditions
Healthy Subjects
Interventions
PF-06751979 single ascending dose, Placebo single dose, PF-06751979 multiple ascending dose, Placebo multiple dose, PF-06751979 multiple dose
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 85 Years
Enrollment
55 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2016
U.S. locations
2
States / cities
Glendale, California
Source: ClinicalTrials.gov public record
Updated Nov 1, 2018 · Synced Oct 16, 2026, 12:22 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Phase 1, Single and Multiple Doses Study of Sitaxentan in Japanese and Western Subjects

NCT00981968
View directory record Official record
Conditions
Healthy
Interventions
Sitaxentan sodium/Placebo
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 55 Years
Enrollment
22 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009
U.S. locations
1
States / cities
Glendale, California
Source: ClinicalTrials.gov public record
Updated Oct 15, 2010 · Synced Oct 16, 2026, 12:22 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Evaluate the Effect of IV Doses of Rivipansel on Subjects With Renal Impairment and in Healthy Subjects

NCT02813798
View directory record Official record
Conditions
Renal Impairment, Healthy
Interventions
Rivipansel
Drug
Lead sponsor
GlycoMimetics Incorporated
Industry
Eligibility
18 Years to 75 Years
Enrollment
28 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2018
U.S. locations
3
States / cities
Anaheim, California • DeLand, Florida • Orlando, Florida
Source: ClinicalTrials.gov public record
Updated Jun 18, 2020 · Synced Oct 16, 2026, 12:22 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Study To Investigate The Safety And Metabolism Of GSK376501 In Overweight Subjects

NCT00495014
View directory record Official record
Conditions
Type 2 Diabetes Mellitus
Interventions
GSK376501, Placebo
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years to 65 Years
Enrollment
70 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007
U.S. locations
1
States / cities
Evansville, Indiana
Source: ClinicalTrials.gov public record
Updated Oct 15, 2010 · Synced Oct 16, 2026, 12:22 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Phase 1 Study to Assess the Safety of NLY01 in Healthy Subjects

NCT03672604
View directory record Official record
Conditions
Safety and Tolerability in Healthy Volunteers
Interventions
NLY01
Drug
Lead sponsor
Neuraly, Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
96 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2019
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Sep 30, 2019 · Synced Oct 16, 2026, 12:22 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Intrapulmonary Pharmacokinetics of XNW4107, Imipenem and Cilastatin in Healthy Subjects

NCT04802863
View directory record Official record
Conditions
Bacterial Infections
Interventions
XNW4107, Imipenem/Cilastatin
Drug
Lead sponsor
Evopoint Biosciences Inc.
Industry
Eligibility
18 Years to 55 Years
Enrollment
21 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021
U.S. locations
1
States / cities
Phoenix, Arizona
Source: ClinicalTrials.gov public record
Updated Feb 16, 2023 · Synced Oct 16, 2026, 12:22 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Safety, Tolerability and Pharmacokinetics of KBP-7072

NCT02454361
View directory record Official record
Conditions
Healthy
Interventions
KBP-7072, Placebo
Drug
Lead sponsor
KBP Biosciences
Industry
Eligibility
18 Years to 45 Years
Enrollment
46 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015
U.S. locations
1
States / cities
Princeton, New Jersey
Source: ClinicalTrials.gov public record
Updated Feb 23, 2024 · Synced Oct 16, 2026, 12:22 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

PK and Safety Study of AG-221 in Healthy Male Japanese Subjects and Healthy Male Caucasian Subjects

NCT02387866
View directory record Official record
Conditions
Healthy
Interventions
AG-221
Drug
Lead sponsor
Celgene
Industry
Eligibility
20 Years to 50 Years · Male only
Enrollment
62 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015
U.S. locations
1
States / cities
Glendale, California
Source: ClinicalTrials.gov public record
Updated Oct 30, 2018 · Synced Oct 16, 2026, 12:22 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

A Safety, Tolerability, Pharmacokinetics And Pharmacodynamics Study Of PF-06700841, With Bioavailability/Food Effect Investigation

NCT02310750
View directory record Official record
Conditions
Plaque Psoriasis
Interventions
PF-06700841 oral solution/suspension, Placebo, PF-06700841 tablet
Drug · Other
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 65 Years
Enrollment
96 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2016
U.S. locations
1
States / cities
Anaheim, California
Source: ClinicalTrials.gov public record
Updated Mar 8, 2017 · Synced Oct 16, 2026, 12:22 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Single and Multiple Ascending Dose Study of LAD603 in Healthy Subjects

NCT06200597
View directory record Official record
Conditions
Healthy Volunteers
Interventions
LAD603, Placebo
Drug · Other
Lead sponsor
Almirall, S.A.
Industry
Eligibility
18 Years to 65 Years
Enrollment
92 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2025
U.S. locations
1
States / cities
Lenexa, Kansas
Source: ClinicalTrials.gov public record
Updated Dec 17, 2025 · Synced Oct 16, 2026, 12:22 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study in Healthy Adult Participants to Assess the Pharmacokinetics, Immunogenicity, Safety, and Tolerability of a Ravagalimab Subcutaneous Formulation in a Pre-Filled Syringe

NCT06402513
View directory record Official record
Conditions
Healthy Volunteers
Interventions
Ravagalimab
Drug
Lead sponsor
AbbVie
Industry
Eligibility
18 Years to 65 Years
Enrollment
12 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024
U.S. locations
1
States / cities
Grayslake, Illinois
Source: ClinicalTrials.gov public record
Updated Oct 21, 2024 · Synced Oct 16, 2026, 12:22 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Two-Part Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of E2006 in Healthy Japanese and White Subjects

NCT02039089
View directory record Official record
Conditions
Healthy Volunteers
Interventions
E2006 2.5 mg, E2006 10 mg, E2006 25 mg, Placebo
Drug
Lead sponsor
Eisai Inc.
Industry
Eligibility
20 Years to 55 Years
Enrollment
32 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014
U.S. locations
1
States / cities
Glendale, California
Source: ClinicalTrials.gov public record
Updated Nov 3, 2015 · Synced Oct 16, 2026, 12:22 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Duvelisib in Hepatically Impaired Subjects Compared to Healthy Subjects

NCT02095587
View directory record Official record
Conditions
Hepatic Impairment
Interventions
IPI-145
Drug
Lead sponsor
SecuraBio
Industry
Eligibility
18 Years to 70 Years
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Mar 17, 2021 · Synced Oct 16, 2026, 12:22 AM EDT
Completed Early Phase 1 Interventional Accepts healthy volunteers

Study of CBP-4888 in Healthy, Non-Pregnant Female Subjects

NCT05881993
View directory record Official record
Conditions
Healthy Volunteer Study
Interventions
CBP-4888, Placebo
Drug · Other
Lead sponsor
Comanche Biopharma
Industry
Eligibility
18 Years to 50 Years · Female only
Enrollment
45 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2024
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Sep 26, 2025 · Synced Oct 16, 2026, 12:22 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of DNL201 in Healthy Volunteers

NCT04551534
View directory record Official record
Conditions
Healthy Volunteers
Interventions
DNL201, Placebo
Drug
Lead sponsor
Denali Therapeutics Inc.
Industry
Eligibility
18 Years to 75 Years
Enrollment
122 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2018
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Sep 16, 2020 · Synced Oct 16, 2026, 12:22 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Safety, Pharmacokinetics, and Pharmacodynamics of SD-101 in Healthy Normal Males

NCT00599001
View directory record Official record
Conditions
Healthy
Interventions
SD-101, placebo
Drug
Lead sponsor
Dynavax Technologies Corporation
Industry
Eligibility
18 Years and older · Male only
Enrollment
26 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Apr 16, 2019 · Synced Oct 16, 2026, 12:22 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Phase 1 Safety Study of Single and Multi-Dose Topically Applied OLT1177 Gel in Healthy Subjects

NCT01636141
View directory record Official record
Conditions
Healthy Volunteers
Interventions
OLT1177 Gel, Placebo gel
Drug
Lead sponsor
Olatec Therapeutics, Inc.
Industry
Eligibility
18 Years to 60 Years
Enrollment
36 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012
U.S. locations
1
States / cities
College Station, Texas
Source: ClinicalTrials.gov public record
Updated Sep 6, 2012 · Synced Oct 16, 2026, 12:22 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Evaluate Pharmacokinetics (PK) and Safety of Inaxaplin in Participants With Renal Impairment

NCT05865171
View directory record Official record
Conditions
Renal Impairment
Interventions
IXP
Drug
Lead sponsor
Vertex Pharmaceuticals Incorporated
Industry
Eligibility
18 Years to 80 Years
Enrollment
16 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2024
U.S. locations
2
States / cities
Ocala, Florida • Tampa, Florida
Source: ClinicalTrials.gov public record
Updated Jul 12, 2024 · Synced Oct 16, 2026, 12:22 AM EDT
Completed Phase 1Phase 2 Interventional Accepts healthy volunteers

Study Designed to Assess the Safety, Tolerability and PK of PTI-808 in Healthy Volunteers and in Adults With Cystic Fibrosis

NCT03251092
View directory record Official record
Conditions
Healthy Volunteer - Complete, Cystic Fibrosis - Complete
Interventions
PTI-808, Placebo, PTI-428, PTI-801
Drug
Lead sponsor
Proteostasis Therapeutics, Inc.
Industry
Eligibility
18 Years to 99 Years
Enrollment
179 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2019
U.S. locations
22
States / cities
Tucson, Arizona • Stanford, California • Denver, Colorado + 18 more
Source: ClinicalTrials.gov public record
Updated Apr 22, 2020 · Synced Oct 16, 2026, 12:22 AM EDT